<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362230</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-006</org_study_id>
    <nct_id>NCT02362230</nct_id>
  </id_info>
  <brief_title>Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy</brief_title>
  <official_title>Sun Yat-sen University Cancer Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in&#xD;
      patients with metastatic triple-negative breast cancer that have received at least two prior&#xD;
      treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, multi-center study. Sixty-seven patients are planned to be enrolled. All&#xD;
      patients will receive Icotinib 125 mg BID administered for 8 weeks. Patients with a complete&#xD;
      response, partial response or stable disease at that time may continue to be treated based on&#xD;
      physician discretion. Follow up is then required until resolution or stabilization of any&#xD;
      treatment-related toxicity, and patients with stable disease or objective responses must also&#xD;
      continue evaluations until survived.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty accruing subjects the study accrual was closed&#xD;
  </why_stopped>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>36 months</time_frame>
    <description>the time from randomization to the date of disease progression or death from any causes</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icotinib 125 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>Icotinib 125 mg BID</description>
    <arm_group_label>Icotinib</arm_group_label>
    <other_name>Conmana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Primary or metastatic tumor onfirmed as triple negative&#xD;
&#xD;
          -  Measurable disease per RECIST version 1.1&#xD;
&#xD;
          -  normal organ function, including bone marrow function, renal function, liver function,&#xD;
             and cardiac function&#xD;
&#xD;
          -  Two or more prior chemotherapy&#xD;
&#xD;
          -  signed and dated an informed consent form&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  ECOG score â‰§2&#xD;
&#xD;
          -  Uncontrolled medical problems&#xD;
&#xD;
          -  Hepatic, renal, or bone marrow dysfunction as detailed above&#xD;
&#xD;
          -  Concurrent malignancy or history of other malignancy within the last five years except&#xD;
             as noted above&#xD;
&#xD;
          -  Patients were unable or unwilling to comply with program requirements&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-Yu Yuan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University, Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 8, 2015</study_first_submitted>
  <study_first_submitted_qc>February 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

